(SGMO) Sangamo Therapeutics - Overview
Stock: Gene Therapy, CAR-Treg, Fabry, Hemophilia A, Kidney Transplant
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 182% |
| Relative Tail Risk | -14.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.54 |
| Alpha | -87.53 |
| Character TTM | |
|---|---|
| Beta | 1.314 |
| Beta Downside | 0.637 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.45% |
| CAGR/Max DD | -0.55 |
Description: SGMO Sangamo Therapeutics January 19, 2026
Sangamo Therapeutics (NASDAQ: SGMO) is a clinical-stage genomic-medicine firm that develops gene-editing and cell-therapy candidates. Its lead programs include ST-920 (Phase 1/2 for Fabry disease), TX200 (Phase 1/2 CAR-Treg to prevent rejection in HLA-A2 mismatched kidney transplants), and SB-525 (Phase 3 gene therapy for moderate-to-severe hemophilia A). Preclinical work targets tauopathies, ALS/FTD, and Huntington’s disease, and the company maintains a network of collaborations with major pharma players such as Biogen, Pfizer, and Novartis.
As of the most recent quarterly filing (Q4 2024), Sangamo reported a cash runway of roughly $180 million and a net loss of $68 million, reflecting the capital-intensive nature of late-stage gene-therapy trials. The SB-525 Phase 3 readout in early 2024 showed a 70 % reduction in annual bleed rates, positioning the asset near a potential FDA filing and a market opportunity estimated at $1.5 billion for hemophilia A gene therapies.
The broader biotech sector is being driven by accelerating regulatory pathways for gene-editing (e.g., FDA’s “Regenerative Medicine Advanced Therapy” designation) and a projected CAGR of 12 % for the global gene-therapy market through 2030. Sangamo’s focus on both systemic (SB-525) and transplant-immune (TX200) applications aligns with these macro trends, but execution risk remains high given the need for durable expression and safety data.
For a deeper quantitative assessment, you may want to explore ValueRay’s analyst tools to compare SGMO’s valuation metrics against sector peers.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -108.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.86 > 0.02 and ΔFCF/TA 19.07 > 1.0 |
| NWC/Revenue: -18.40% < 20% (prev 28.63%; Δ -47.03% < -1%) |
| CFO/TA -0.86 > 3% & CFO -76.2m > Net Income -108.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (304.3m) vs 12m ago 41.97% < -2% |
| Gross Margin: 87.73% > 18% (prev 0.80%; Δ 8693 % > 0.5%) |
| Asset Turnover: 32.89% > 50% (prev 47.00%; Δ -14.11% > 0%) |
| Interest Coverage Ratio: -84.03 > 6 (EBITDA TTM -102.8m / Interest Expense TTM -1.32m) |
Altman Z'' -15.00
| A: -0.07 (Total Current Assets 44.1m - Total Current Liabilities 50.1m) / Total Assets 88.6m |
| B: -17.94 (Retained Earnings -1.59b / Total Assets 88.6m) |
| C: -1.11 (EBIT TTM -110.7m / Avg Total Assets 100.0m) |
| D: -19.27 (Book Value of Equity -1.59b / Total Liabilities 82.4m) |
| Altman-Z'' Score: -86.59 = D |
Beneish M -3.82
| DSRI: 0.78 (Receivables 5.12m/10.5m, Revenue 32.9m/52.3m) |
| GMI: 0.92 (GM 87.73% / 80.48%) |
| AQI: 1.19 (AQ_t 0.17 / AQ_t-1 0.15) |
| SGI: 0.63 (Revenue 32.9m / 52.3m) |
| TATA: -0.37 (NI -108.9m - CFO -76.2m) / TA 88.6m) |
| Beneish M-Score: -3.82 (Cap -4..+1) = AAA |
What is the price of SGMO shares?
Over the past week, the price has changed by -29.57%, over one month by -11.15%, over three months by -22.21% and over the past year by -65.52%.
Is SGMO a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SGMO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.8 | 852.5% |
| Analysts Target Price | 3.8 | 852.5% |
| ValueRay Target Price | 0.2 | -45% |
SGMO Fundamental Data Overview February 03, 2026
P/B = 28.8632
Revenue TTM = 32.9m USD
EBIT TTM = -110.7m USD
EBITDA TTM = -102.8m USD
Long Term Debt = 25.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.31m USD (from shortTermDebt, last fiscal year)
Debt = 25.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.10m USD (from netDebt column, last quarter)
Enterprise Value = 175.1m USD (180.2m + Debt 25.4m - CCE 30.5m)
Interest Coverage Ratio = -84.03 (Ebit TTM -110.7m / Interest Expense TTM -1.32m)
EV/FCF = -2.29x (Enterprise Value 175.1m / FCF TTM -76.4m)
FCF Yield = -43.63% (FCF TTM -76.4m / Enterprise Value 175.1m)
FCF Margin = -232.4% (FCF TTM -76.4m / Revenue TTM 32.9m)
Net Margin = -331.3% (Net Income TTM -108.9m / Revenue TTM 32.9m)
Gross Margin = 87.73% ((Revenue TTM 32.9m - Cost of Revenue TTM 4.03m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.98 (Enterprise Value 175.1m / Total Assets 88.6m)
Interest Expense / Debt = 447.8% (Interest Expense 113.8m / Debt 25.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -87.4m (EBIT -110.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.88 (Total Current Assets 44.1m / Total Current Liabilities 50.1m)
Debt / Equity = 4.07 (Debt 25.4m / totalStockholderEquity, last quarter 6.24m)
Debt / EBITDA = 0.05 (negative EBITDA) (Net Debt -5.10m / EBITDA -102.8m)
Debt / FCF = 0.07 (negative FCF - burning cash) (Net Debt -5.10m / FCF TTM -76.4m)
Total Stockholder Equity = 13.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -109.0% (out of range, set to none)
RoE = -814.0% (Net Income TTM -108.9m / Total Stockholder Equity 13.4m)
RoCE = -285.2% (out of range, set to none) (EBIT -110.7m / Capital Employed (Equity 13.4m + L.T.Debt 25.4m))
RoIC = -653.4% (out of range, set to none) (NOPAT -87.4m / Invested Capital 13.4m)
WACC = 9.43% (E(180.2m)/V(205.6m) * Re(10.76%) + (debt cost/tax rate unavailable))
Discount Rate = 10.76% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 30.88%
Fair Price DCF = unknown (Cash Flow -76.4m)
EPS Correlation: 48.75 | EPS CAGR: 16.70% | SUE: 0.50 | # QB: 0
Revenue Correlation: -50.48 | Revenue CAGR: -64.42% | SUE: -2.38 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.23 | Chg30d=+0.073 | Revisions Net=+1 | Growth EPS=+43.9% | Growth Revenue=-15.5%